IndiaCOVID-19Ministry of Health and Family WelfareHealth

COVID – 19 Vaccination Update – Day 384

India’s cumulative vaccination coverage crosses 168.40 crore. More than 50 lakh Vaccine doses administered today till 7pm

India’s COVID-19 vaccination coverage has crossed 168.40 Crore (168,40,41,689) today. More than 50 lakh (50,11,156) Vaccine Doseshave been administered till 7 pm today. More than 1.38 Crore(1,38,82,262) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10396902
2nd Dose 9890705
Precaution Dose 3557041
FLWs 1st Dose 18399332
2nd Dose 17291007
Precaution Dose 4392678
Age Group 15-18 years 1st Dose 48258993
  2nd Dose 3411019
Age Group 18-44 years 1st Dose 543375381
2nd Dose 412230355
Age Group 45-59 years 1st Dose 200719050
2nd Dose 173130114
Over 60 years 1st Dose 125188217
2nd Dose 107868352
Precaution Dose 5932543
Cumulative 1st dose administered 946337875
Cumulative 2nd dose administered 723821552
Precaution Dose 13882262
Total 1684041689

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 3rdFebruary, 2022 (384thDay)
HCWs 1st Dose 252
2nd Dose 4046
Precaution Dose 45376
FLWs 1st Dose 658
2nd Dose 10318
Precaution Dose 117620
Age Group 15-18 years 1st Dose 453972
  2nd Dose 1211491
Age Group 18-44 years 1st Dose 529540
2nd Dose 1637059
Age Group 45-59 years 1st Dose 91274
2nd Dose 373101
Over 60 years 1st Dose 64538
2nd Dose 225081
Precaution Dose 246830
Cumulative 1st dose administered 1140234
Cumulative 2nd dose administered 3461096
Precaution Dose 409826
Total 5011156

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button